Sub Sector: Exits - Healthcare


ViaCell is focused in the area of women’s health and conducts R&D to investigate potential therapeutic uses of umbilical cord blood derived stem cells. Acquired by Perkin Elmer in 2007.


Vanda Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. Listed on NASDAQ in 2006.


U3 Pharma is a leader in the field of targeted cancer drug development. Acquired by Daiichi Sankyo in 2008.


Revance Therapeutics is developing the next generation of innovative products in dermatology and aesthetic medicine. Listed on NASDAQ in 2014.


Paradigm Therapeutics has developed a promising pipeline of novel drug discovery targets and compounds for pain, CNS disorders, prostate and breast cancer, diabetes, hyperlipidemia, and obesity. Acquired by Takeda Pharmaceutical in 2007


OptiMedica designs, develops, and commercialises technologies to treat major eye diseases and disorders. Acquired by Abbott Medical Optics in 2013.


NeuroVision trains the brain to see sharper by performing a series of NeuroVision patented, computerised and customised visual tasks.


Moderna pioneers the discovery and development of messenger RNA (mRNA) therapeutics and vaccines, an entirely new class of medicines that directs the body’s cells to produce intracellular or secreted proteins that can have a therapeutic or preventive benefit for both patients and healthy individuals. Listed on NASDAQ in 2018.


MerLionPharma is progressing finafloxacin, a novel antibacterial candidate, for the treatment of urinary tract infections and the eradication of Helicobacter pylori in critical care and hospital indications.


Maccine is a preclinical contract research organisation providing innovative discovery research and quality safety-assessment services to the global biotechnology and pharmaceutical industry.